Résultats de la recherche - B. Zurawski

  • Résultat(s) 1 - 4 résultats de 4
Affiner les résultats
  1. 1
    LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial

    LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized,... par Robert J. Motzer, Paul Russo, Viktor Gruenwald, Y Tomita, B. Zurawski, Omi Parikh, S. Buti, Philippe Barthélémy, J.C.H. Goh, D. Ye, Alejo Lingua, J-B. Lattouf, Bernard Escudier, Saby George, Brian Shuch, Burçin Şimşek, J. Spiridigliozzi, A. Chudnovsky, A. Bex

    Publié 2022
    Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  2. 2
    1049P Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA

    1049P Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone for me... par T. John, T. Ciuleanu, M. Cobo Dols, M. Schenker, B. Zurawski, J. Menezes, E.A. Richardet, J. Bennouna, Y. Cheng, E. Felip, Óscar Juan, A. Alexandru, L. Paz-Ares, S. Lu, M. Reck, N. Hu, X. Zhang, D.J. Grootendorst, L. Eccles, D.P. Carbone

    Publié 2022
    Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  3. 3
    LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)

    LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or p... par Toni K. Choueiri, Tom Powles, Laurence Albigès, M. Burotto, C. Szczylik, B. Zurawski, E. Yanez Riuz, Marco Maruzzo, Alberto Suárez Zaizar, Luis Fein, Fabio A. Schutz, Daniel Yick Chin Heng, F. Wang, Fabio Mataveli, Yih‐Leong Chang, Maximiliano van Kooten Losio, C. Suárez Rodríguez, Robert J. Motzer

    Publié 2022
    Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:
  4. 4
    1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study

    1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-64... par Julie N. Graff, Mauricio Burotto, Peter C.C. Fong, David Pook, B. Zurawski, Ray Manneh Kopp, Judith Salinas, Kathryn Bylow, Gero Kramer, Raffaele Ratta, Mariusz Kwiatkowski, Margitta Retz, Cheol Kwak, José Ángel Arranz Arija, Howard Gurney, Nobuaki Matsubara, Li Liang, Jelena Todoric, Kentaro Imai, Arnulf Stenzl

    Publié 2023
    Accéder au texte intégral Accéder au texte intégral
    Artigo
    Ajouter aux favoris
    Enregistré dans:

Outils de recherche: